SEOUL, South Korea & AHMEDABAD, India & ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Enzychem Lifesciences (KOSDAQ: 183490) and Cadila Healthcare Ltd, a part of the Zydus Group, today announced that they have entered a Manufacturing License and Technology Transfer Agreement for the world’s first plasmid DNA vaccine (ZyCoV-D®). Following the results of a large clinical trial involving nearly 30,000 subjects, ZyCoV-D® was recently granted emergency use approval (EUA) by India’s national regulatory agency for subjects 12 years and above.
Under the terms of this agreement, Zydus shall transfer its manufacturing technology and provide technical assistance to Enzychem. Both CHL and Enzychem believe that this partnership will lead to estimated manufacturing of 80 million or more doses of the plasmid DNA vaccine in 2022. Accordingly, Enzychem shall pay Zydus license fees and royalties for the commercialization of the Plasmid DNA-based COVID-19 vaccine made in Korea and exported to a number of countries, including low-medium income countries (LMICs) in Latin America and Asian New Southern Policy member countries.
Mr. Ki Young Sohn, Chairman of Enzychem Lifesciences said: “Today marks an important milestone for our vaccine consortium as we embark on the manufacturing of the world’s first- in-class DNA vaccine for humans. This technology allows vaccines to be produced at affordable costs in record time, and DNA vaccines are considerably stable. The vaccine is administered intradermally using the PharmaJet®needle free applicator, which ensures painless intradermal vaccine delivery and can thus be deployed more readily, especially in resource-poor populations where these are urgently needed. With state-of-the-art manufacturing facilities and a qualified workforce dedicated to manufacturing high quality products, we are very eager to partner with Zydus in addressing the global demand for COVID vaccines, especially in low-medium income countries.”
Speaking on the development, Dr. Sharvil Patel, Managing Director, Cadila Healthcare Ltd., said, “We are very happy to partner with Enzychem Lifesciences and provide access to the technology behind the needle-free, Plasmid DNA vaccine technology which is the first of its kind in the world. Our aim is to provide new innovations and novel technologies that can support people with better approaches to healthcare. This agreement enables people in South Korea and other key markets of Enzychem, the access to a safe, well tolerated and efficacious vaccine with a novel platform to fight COVID-19.”
Headquartered in Seoul, South Korea, Enzychem Lifesciences (KOSDAQ:183490) is developing novel small molecule therapeutics to target fundamental pathways in inflammation, patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases. Enzychem lead candidate, EC-18, has successfully completed US FDA phase 2 clinical testing in cancer patients. In response to the Korean government pledge for a Vaccine Hub, Enzychem has formed a consortium with Hanmi Pharma and several domestic companies in Korea to manufacture vaccines against COVID 19. The company plans to leverage its expertise in lipid chemistry and manufacturing to establish itself as a regional producer of lipid-based formulations for improved delivery of nucleic acids and other biologicals and drugs. For more information, please visit www.enzychem.com.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is dedicated to creating healthier communities globally.
The content is by Business Wire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.